UNIGE document Scientific Article
previous document  unige:7576  next document
add to browser collection
Title

Influence of rifampin on fleroxacin pharmacokinetics

Authors
Weidekamm, E.
Portmann, R.
Published in Antimicrobial Agents and Chemotherapy. 1993, vol. 37, no. 10, p. 2132-2138
Abstract Staphylococcus aureus infections have been successfully treated in animal models with the combination of fleroxacin and rifampin. We studied the influence of rifampin, a potent cytochrome P-450 inducer, on the pharmacokinetics and biotransformation of fleroxacin in 14 healthy young male volunteers. Subjects were given 400 mg of fleroxacin orally once a day for 3 days to reach steady state. After a wash-out period of 2 days, the same subjects received 600 mg of rifampin orally once daily for 7 days. On days 5 to 7 of rifampin treatment, 400 mg of fleroxacin was again administered once daily. Concentrations of fleroxacin as well as its two major urinary metabolites, N-demethyl- and N-oxide-fleroxacin, in plasma and urine were determined by reverse-phase high-performance liquid chromatography. The extent of hepatic enzyme induction by rifampin was confirmed by a significant increase of 6-beta-hydroxycortisol urinary output from 160.8 +/- 41.4 to 544.8 +/- 120.7 micrograms/4 h. There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min). The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01). Despite being statistically significant, this 15% increase in total plasma clearance does not appear to be clinically relevant. Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min). Fleroxacin elimination was slightly increased (about 15%) through induction of metabolic clearance to N-demethyl-fleroxacin. Since fleroxacin levels remained above the MIC for 90% of the tested isolates of methicillin-susceptible S. aureus for at least 24 h, dose adjustment does not appear necessary, at least for short-term treatments.
Keywords AdultAnti-Bacterial AgentsCytochrome P-450 Enzyme System/biosynthesisDose-Response Relationship, DrugDrug Therapy, Combination/pharmacologyEnzyme InductionFleroxacin/adverse effects/ pharmacokineticsHumansHydrocortisone/analogs & derivatives/urineLiver/drug effects/enzymologyMaleRifampin/adverse effects/ pharmacologyStaphylococcal Infections/drug therapy
Identifiers
PMID: 8257135
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://aac.asm.org/cgi/reprint/37/10/2132.pdf
Structures
Citation
(ISO format)
SCHRENZEL, Jacques et al. Influence of rifampin on fleroxacin pharmacokinetics. In: Antimicrobial Agents and Chemotherapy, 1993, vol. 37, n° 10, p. 2132-2138. https://archive-ouverte.unige.ch/unige:7576

242 hits

0 download

Update

Deposited on : 2010-06-21

Export document
Format :
Citation style :